The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 3, 2013, Pages 258-264

  Crook, Juanita ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hormonal therapy; Intermittent androgen suppression; Prostate neoplasms

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

BONE TUMOR; CANCER GRADING; DRUG ADMINISTRATION; HUMAN; MALE; METASTASIS; MORTALITY; PATHOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; BONE NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887986390     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328363602e     Document Type: Review

References (26)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168:9-12.
2. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71:2782-2790.
3. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58:139-146.
4. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58:2546-2550.
5. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48:800-804.
6. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51:137-144.
7. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol 1999; 3:287-292.
8. Prapotnich D, Fizazi K, Escudier B, et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43:233-239; discussion 239-240.
9. Bouchot O, Lenormand L, Karam G, et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38:543-549.
10. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000; 5:45-52.
11. Sciarra A, Di Chiro C, Di Silverio F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 2000; 18:392-400.
12. Pether M, Goldenberg SL, Bhagirath K, Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003; 10:1809-1814.
13. De La Taille A, Zerbib M, Conquy S, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003; 91:18-22.
14. Lane TM, Ansell W, Farrugia D, et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73:117-122.
15. Malone S, Perry G, Segal R, et al. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 2005; 96:514-520.
16. Cury FL, Souhami L, Rajan R, et al. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 64:842-848.
17. Bruchovsky N, Klotz L, Crook J, et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006; 107:389-395.
18. Spry NA, Kristjanson L, Hooton B, et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42:1083-1092.
19. Calais da Silva F, Bono A, Whelan P, et al. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group. Oncology 2003; 65 (Suppl 1):24-28.
20. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269-1277.
21. Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 2012; 15:296-302.
22. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1:163-171.
23. Yamanaka H, Ito K, Naito S, et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 2005; 63:56-64.
24. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367:895-903.
25. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314-1325.
26. Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-1160.